Anika Therapeutics, Inc. (ANIK) Stock Score, Valuation & Financial Research
Anika Therapeutics, Inc. is in the Healthcare sector and Medical - Specialties industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 26/100.
Quick answer for ANIK
Anika Therapeutics, Inc. currently has a Wall Street Score of 26/100. The stored market price is $20.86. Its financial score is 30/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Anika Therapeutics, Inc. does
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue
ANIK financial snapshot
- Wall Street Score:
- 26/100
- Current price:
- $20.86
- Market capitalization:
- $279.2M
- Revenue:
- $120.7M
- Net income:
- $-3.8M
- Free cash flow:
- $4.4M
- Cash:
- $38.4M
- Total debt:
- $23.3M
- EPS:
- -0.27
- Financial score:
- 30/100
- Valuation score:
- 0/100
- Revenue score:
- 11/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $4.4M, showing positive cash generation.
- The balance sheet shows $38.4M of cash versus $23.3M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 30/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ANIK
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.